NEUROCLUES DECODES THE BRAIN IN THE BLINK OF AN EYE
April 10, 2026
"We designed the product with clinicians, conducting more than 100 user interviews right from the start, so that it integrates perfectly into their practice"
Already deployed in seven countries just months after its CE marking, the Belgian medtech raises €10M to industrialize its medical device based on
eye movement analysis, enabling objective neurological assessment.
Just months after obtaining its class IIa CE marking, neuroClues reports a presence in seven European countries - France, Belgium, Germany, Italy, Switzerland, the Netherlands and the United Kingdom - with more than 30 devices installed in hospitals, neurology practices and research institutes. The Belgian medtech, which has been generating its first reven...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.
Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.
RELATED ARTICLES
Qubit Pharmaceuticals Sets Course for Applied Quantum
By entering into a partnership with the Centre for Quantum Technologies (CQT) in Singapore, the French deeptech Qubit Pharmaceuticals is testing the f
SENSOME: PHYSICAL AI ENTERS THE ARTERIES OF THE BRAIN
The neurovascular market is boiling: Boston Scientific has just acquired Penumbra for $14.5bn, while Medtronic is set to swallow Scienta Vascular for
THERASONIC: 2ND FUNDRAISING BY SUMMER
2026 looks set to be a pivotal year for the young Medtech. On its agenda: a fundraising round of at least €2M, the start of a clinical trial and the s